How effective are nonalcoholic fatty liver disease models for drug discovery?

Taylor and Francis Group, Expert Opinion on Drug Discovery, 11(15), p. 1237-1240, 2020

Journal article published in 2020 by Jana Hundertmark

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by